KCA-ASCO Young Investigator Award

KCA and the and the ASCO Grants Selection Committee announce the selection of the 2007 Young Investigator Award:Patricia Tang, MD, Princess Margaret HospitalAbstractWith the advent of anti-angiogenic therapies (AAT) for cancer treatment, a number of adverse effects have been identified in patients; importantly these include proteinuria (due to disruption of the glomerular filtration barrier) and hypertension.    Hypertension appears to be a class effect of AAT, whereas proteinuria has been reported with bevacizumab, VEGF Trap, and AZD2171.  The physiological mechanisms underlying the hypertension and proteinuria caused by anti-angiogenic therapies are not well understood.Vascular endothelial growth factor (VEGF)-A expression is maintained in a few specialized microvascular beds in the adult including the kidney glomerulus.  When the VEGF-A gene is deleted from podocytes of adult mice, mice develop proteinuria, hypertension, and glomerular disease.  Strikingly, biopsies taken from 3 patients who developed nephrotic range proteinuria after starting AAT, demonstrate the identical renal lesion.  The similarity between genetic and pharmacologic knockdown of VEGF-A in mice and patients, respectively, suggest that the side effects are due to "on target effects" from anti-VEGF treatment.This clinical study will characterize the renal and blood pressure changes in patients treated with AZD2171 or VEGF Trap on phase II trials conducted throu...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

ConclusionSGLT2 inhibitors have relatively safe profiles and can efficiently decrease HbA1c as well as fasting and postprandial glucose levels. Furthermore, SGLT2 inhibitors administrations are not associated with significant hypoglycemic episodes or weight gain. Thus, combination of SGLT2 inhibitors and other less harmful anti-diabetic medicines could be considered if there is no any contraindication.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
ConclusionThere is need to improve both the knowledge base and comfort level of pediatricians in counseling their patients during vaccine recommendations. Otolaryngologists have a critical role in providing education to physicians, trainees, and the general public in the effort to combat the epidemic of HPV-associated head and neck cancer.
Source: American Journal of Otolaryngology - Category: Endocrinology Source Type: research
Conclusion: Our findings establish PLAC8 as a central mediator of cell growth in a subset of human PanNET, providing evidence for the existence of distinct molecular subtypes within this class of tumors.
Source: Neuroendocrinology - Category: Endocrinology Source Type: research
In conclusion, the spectrum of autoimmune reactions induced by immune-checkpoint inhibitors should be restricted in the near future to only these specific favorable autoimmune mechanisms. In this way, the unnecessary autoimmune reactions/autoaggressions could be avoided (a better quality of life), and treatment specificity and efficiency should increase (a higher response rate for melanoma therapy).
Source: Melanoma Research - Category: Cancer & Oncology Tags: REVIEW ARTICLES Source Type: research
In this study, we report a case of cardiovascular adverse events of aortic dissection and cardiac dysfunction during treatment with sorafenib and axitinib for metastatic renal cell carcinoma. A 66-year-old man had been administered sorafenib for 2 years after nephrectomy due to renal cell carcinoma. To control the progression of metastatic lung tumor, axitinib was started after sorafenib for four years. During the treatment, angiotensin II type 1 receptor blockers and Ca antagonists were used to strictly control the axitinib-induced hypertension and proteinuria. Aortic dissection and cardiac dysfunction occurred coincident...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
In conclusion, cellular immunotherapy and oncolytic therapy for cancer may be improved by the synergistic effects of lenvatinib and sensitized lymphocytes. In the present study, the inherent antineoplastic and immune stimulatory properties of the two agents were enhanced when used in combination, which may provide a basis for clinical treatment of patients with RCC. PMID: 28912872 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
CONCLUSION: Based on this initial experience at our center, pazopanib seems a feasible first-line treatment for mRCC due to its well-tolerable toxicity profile. However, larger data are required to confirm its efficacy in Indian patients.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 23 September 2016 Source:Autoimmunity Reviews Author(s): Francesca Saccon, Mariele Gatto, Anna Ghirardello, Luca Iaccarino, Leonardo Punzi, Andrea Doria Galectins are evolutionary conserved β-galactoside binding proteins with a carbohydrate-recognition domain (CRD) of approximately 130 amino acids. In mammals, 15 members of the galectin family have been identified and classified into three subtypes according to CRD organization: prototype, tandem repeat-type and chimera-type galectins. Galectin-3 (gal-3) is the only chimera type galectin in vertebrates containing one CRD linked to a...
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
CONCLUSION: Our study shows that most patients undergoing nephrectomy for cancer are able to follow HBPM. It should be encouraged for detecting high BP or proteinuria, especially if antiangiogenic therapies are envisaged because of the supplementary risk of hypertension and proteinuria induced by these treatments. PMID: 25531211 [PubMed - indexed for MEDLINE]
Source: Blood Pressure - Category: Hematology Tags: Blood Press Source Type: research
Conclusions: The safety profile of axitinib in HCC CPA and CPB pts in this study was consistent with the known safety profile of axitinib. Axitinib plasma exposures were comparable in CPB pts receiving 2 mg BID axitinib and CPA pts receiving 5 mg BID axitinib. These data are in agreement with the previous single-dose HI study and further support that 2 mg BID is an appropriate axitinib starting dose for CPB pts with HCC.Citation Format: Yoon-Koo Kang, Tara E. Seery, Mina Kato, Debasis Chakrabarti, Olga Valota, Ying Chen, Jie Tang, Yazdi K. Pithavala, Masatoshi Kudo. Axitinib safety and pharmacokinetics in Child-Pugh A and ...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Clinical Trials Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Genetics | Grants | Hypertension | Kidney Cancer | Proteinuria | Study | Urology & Nephrology